Novavax (NVAX) Consolidated Net Income (2010 - 2026)

Novavax's Consolidated Net Income history runs 17 years deep, the most recent figure standing at -$9.5 million for Q1 2026.

• In Q1 2026, Consolidated Net Income fell 101.83% year-over-year to -$9.5 million; the TTM figure through Mar 2026 stood at -$87.8 million (down 118.35% YoY), while the FY2025 annual figure was $440.3 million, up 334.83% from the prior year.
• Consolidated Net Income was -$9.5 million for Q1 2026 at Novavax, down from $17.5 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $518.6 million in Q1 2025 to a low of -$510.5 million in Q2 2022.
• Historically, Consolidated Net Income has averaged -$56.5 million across 5 years, with a median of -$121.3 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Consolidated Net Income slumped 244.49% in 2023, then soared 451.51% in 2025.
• A 5-year view of Consolidated Net Income shows it stood at -$182.2 million in 2022, then rose by 2.12% to -$178.4 million in 2023, then jumped by 54.58% to -$81.0 million in 2024, then jumped by 121.63% to $17.5 million in 2025, then plunged by 154.15% to -$9.5 million in 2026.
• The last three Consolidated Net Income figures came in at -$9.5 million (Q1 2026), $17.5 million (Q4 2025), and -$202.4 million (Q3 2025), per Business Quant data.